This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (9)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Clinical and Investigational Perspective

Richard L. Burleson, MD; Richard J. Kronhaus, MD; Peter D. Marbarger, MD; David M. Jones, MD

Arch Surg. 1982;117(7):933-935.

Abstract
• Upper gastrointestinal (GI) tract complications have been a substantial cause of death following renal transplantation. Cimetidine, an H₂ receptor antagonist, has been used in the posttransplant period to decrease this hazard. However, H₂ receptor antagonists may enhance the immune response and be deleterious for the graft. The magnitude of the hazard of upper GI tract complications after renal transplantation was determined by reviewing 200 renal transplants. The effect of cimetidine treatment on the survival of canine renal allografts was investigated. The upper GI tract complication rate was 1.5% with one related death (0.5%). Treatment of dogs with cimetidine shortened the survival time of renal allografts (18.2 ± 5.5 [SE] days to 12.5 ± 2.2 days). Because upper GI tract complications are not a major hazard and H₂ receptor antagonist therapy may decrease the survival of dog renal allografts, we believe prophylactic use of cimetidine is not indicated.

(Arch Surg 1982;117:933-935.

Author Affiliations
From the Organ Transplant Service (Dr Burleson) and the Departments of Surgery (Drs Burleson and Marbarger), Urology (Drs Burleson and Kronhaus), and Pathology (Dr Jones), State University of New York, Upstate Medical Center, Syracuse.

Footnotes
Accepted for publication Nov 5, 1981.

Reprint requests to Department of Surgery, State University of New York, Upstate Medical Center, Syracuse, NY 13210 (Dr Burleson).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?